HC Wainwright Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX)

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research note released on Monday,Benzinga reports. The firm currently has a $24.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Wedbush restated an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 21st. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. Finally, Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, February 10th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $13.38.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock traded down $0.18 on Monday, reaching $1.94. The company had a trading volume of 877,992 shares, compared to its average volume of 877,620. The firm has a market cap of $268.27 million, a price-to-earnings ratio of -5.24 and a beta of 1.40. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The firm's 50-day moving average price is $2.23 and its two-hundred day moving average price is $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the company's stock in a transaction dated Monday, April 7th. The shares were acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the business. Barclays PLC grew its stake in shares of Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after acquiring an additional 356,352 shares during the period. Geode Capital Management LLC lifted its stake in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock valued at $4,251,000 after acquiring an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock valued at $58,000 after purchasing an additional 28,589 shares during the last quarter. Finally, Independent Advisor Alliance bought a new position in Compass Therapeutics during the fourth quarter worth about $26,000. Institutional investors and hedge funds own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.